

PTO FAX NO.: 1.703.746.9195  
TELEPHONE NO.: 1.703.308.1202

**OFFICIAL COMMUNICATION**  
**FOR THE ATTENTION OF**  
**Office of Initial Patent Examination**  
**(OIPE)**

**CERTIFICATION OF FACSIMILE TRANSMISSION**

I hereby certify that the following document(s) in re Application of Phylonix Pharmaceuticals, Inc., Application No. 10/766,134, filed January 27, 2004 for METHODS FOR INTRODUCING HETEROLOGOUS CELLS INTO FISH TO DETERMINE IF THE HETEROLOGOUS CELLS CONTAIN CANCER CELLS OR A PATHOGEN (AMENDED) is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Document(s) Attached

1. Transmittal Form
2. Request for Corrected Filing Receipt
3. Copy of Corrected Filing Receipt
4. Supplemental Application Data Sheet

Number of pages being transmitted, including this page: 10

Dated: July 6, 2004


  
Janet L. Newmaker


**PLEASE CONFIRM RECEIPT OF THIS PAPER BY**  
**RETURN FACSIMILE AT (303) 571-4321**

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, CA 94111-3834  
Telephone: 303-571-4000  
Fax: 303-571-4321  
60254509 v1

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after Initial filing)</i>		Application Number	10/766,134
		Filing Date	January 27, 2004
		First Named Inventor	George N. Serbedzija
		Art Unit	1645
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission		Attorney Docket Number	018852-000610US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Request For Corrected Filing Receipt Filing Receipt Supplemental Application Data Sheet
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Townsend and Townsend and Crew LLP Scott L. Aussenhus Reg. No. 42,271
Signature	
Date	July 6, 2004

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, Fax No. (703) 746-9195 on July 6, 2004.			
Typed or printed name	Janet L. Newmaker		
Signature		Date	July 6, 2004
60254529 v1			

JUL. 6. 2004 4:15PM

TOWNSEND & TOWNSEND

NO. 6093 P. 3/10

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-703-746-9195 on July 6, 2004.

**PATENT**  
Attorney Docket No.: 018852-000610US

TOWNSEND and TOWNSEND and CREW LLP

By:

*Janet L. Newmaker*

Janet L. Newmaker

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

George N. Serbedzija et al.

Application No.: 10/766,134

Filed: January 27, 2004

For: METHODS FOR INTRODUCING  
HETEROLOGOUS CELLS INTO  
FISH TO DETERMINE IF THE  
HETEROLOGOUS CELLS  
CONTAIN CANCER CELLS OR A  
PATHOGEN  
(AMENDED)

Customer No. 20350

Confirmation No.: 1970

Examiner: Not Assigned

Art Unit: 1645

REQUEST FOR CORRECTED FILING  
RECEIPT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Attached is a copy of the official Filing Receipt received from the Patent and Trademark Office for the above-identified application for which issuance of a corrected filing receipt is respectfully requested. The requested correction is indicated. Also attached is a Supplemental Application Data Sheet, which reflects these changes.

There is an error in that the "Title" section should read as follows:

Methods For Introducing Heterologous Cells Into Fish To Determine If The  
Heterologous Cells Contain Cancer Cells Or A Pathogen

George N. Serbedzija et al.  
Application No.: 10/766,134  
Page 2

PATENT

A corrected filing receipt is respectfully requested. Applicants believe no fee is required for submission of this request. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430.

Respectfully submitted,



Date: July 6, 2004

Scott L. Ausenhus  
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 303-571-4000  
Fax: 303-571-4321  
SLA/jln  
60254342 v1



**Title**

Methods for introducing heterologous cells into fish to determine if the ~~heterologous~~ <sup>heterologous</sup> cells contain cancer cells or a pathogen

**Preliminary Class**

435

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 600+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).